The American College of Rheumatology has issued a series of COVID-19 guiding principles for healthcare professionals who treat patients with rheumatic disease. In this quiz, we highlight a few of the key points the organization, and other healthcare experts, have made in recent weeks.
The American College of Rheumatology recommends treating rheumatoid arthritis early in order to increase the chances of achieving and sustaining remission. Take our clinical quiz to learn more.
The risk of dying from a cardiovascular event can increase by 50 percent for rheumatoid arthritis patients with low serum folate levels, report researchers in JAMA Open Network.
Early rheumatoid arthritis is, in part, defined as having symptoms for at least six months. Beyond six months, it's considered established rheumatoid arthritis. But diagnosing early rheumatoid arthritis is not that straightforward. Serologic tests can confirm a clinical diagnosis, but these tests aren't always reliable and can be negative in about 50 percent of rheumatoid arthritis cases. In this quiz, we focus on the diagnosis and treatment of early rheumatiod arthritis.
The findings can lead to new policies, procedures, and programs being implemented at health systems.
Respiratory viral infections can be a novel environmental risk factor for the development of rheumatoid arthritis, find Korean researchers writing in Arthritis Research and Therapy.
What is the connection (if any) between coronavirus and autoimmune diseases? In this slideshow, we feature some points of view from rheumatology experts in the field, including Dr. Jean Liew of the University in Washington, Seattle, who told CreakyJoints that patients with inflammatory arthritis are probably more susceptible to the coronavirus and are at higher risk of complications like pneumonia.
A two-pronged vaccination approach performs better than a single pneumococcal vaccination in patients receiving conventional DMARDs or abatacept-treated patients, but not in patients receiving rituximab, say researchers writing in Arthritis Research & Therapy.
Providers who care for patients with asthma or COPD need to be aware of the increased risk of rheumatoid arthritis.
Bone mineral density was preserved over a three-year period in patients with rheumatoid arthritis treated with biological/targeted synthetic disease-modifying antirheumatic drugs (DMARDS) but declined in those who received only conventional-synthetic DMARDs, say researchers recently writing in Rheumatology.
Research from the University of Texas examines how serum folate levels above or below a certain level were linked to an increase in cardiovascular mortality.
A study of 312,081 pregnant women with rheumatoid arthritis, spondyloarthritis or no inflammatory arthritis, finds that women with rheumatoid arthritis are more likely to have pregnancy complications.
A double-blind, placebo-controlled, randomized clinical trial has confirmed that low-dose methotrexate is associated with an increased risk of skin cancer, according to a study published this week in the Annals of Internal Medicine.
New treatments for rheumatoid arthritis can effectively control inflammation, but they do little to improve quality of life indicators-like fatigue-that are important to patients, shows a new study.
The therapeutic management of rheumatoid arthritis has changed over the past 30 years, yet, comorbidities persist. In this quiz, we focus on findings from a new study that examines trends in clinical and patient-reported outcomes for early RA.
Women with rheumatoid arthritis who adhered to a defined program involving diagnostic, therapeutic, and prenatal care recommendations restored the risk of adverse pregnancy outcomes to that expected in the general population, say researchers recently writing in Arthritis Care & Research.
In this month's rheumatoid arthritis quiz, we focus on tests used to diagnose rheumatoid arthritis as there are plenty. In this quiz, we focus on the most commonly ordered tests used to evaluate a patient who may have rheumatoid arthritis.
Disease activity measures still don’t appear to be entirely aligned with patient perceptions of pain and disease activity, shows a study featured in today’s news roundup. Researchers writing in Rheumatology say that condition improvements seen in objective measures of rheumatoid arthritis (RA) disease activity over the past three decades, do not match improvements in patient reported outcomes such as mental health, functional disability, overall disease activity, pain and vitality/fatigue. Learn more about this and other recently published studies on rheumatoid arthritis.
In today's news roundup, we look back at some of this week's most popular stories on Rheumatology Network. We begin with a report on the right vaccine dose for rheumatoid arthritis patients.
In patients with seropositive rheumatoid arthritis, high-dose trivalent inactivated influenza vaccine (HD-TIV) is safe and more immunogenic than standard-dose quadrivalent influenza vaccine (SD-QIV), say researchers writing in The Lancet Rheumatology.
Rheumatoid arthritis patients have an increased risk of developing cardiovascular disease, yet rheumatologists and primary care physicians who treat RA patients sometimes miss the signs and symptoms of CVD in their patients. Learn more in this slideshow.
The placebo response in clinical trials for rheumatoid arthritis appears to have grown over the last two decades with patients exhibiting significant improvements in pain scores with placebo treatment.
How strong is the familial link in rheumatoid arthritis? The answer may surprise you. Test your knowledge in this quiz.
The JAK inhibitor upadacitinib was approved last August for the treatment of moderate to severe rheumatoid arthritis. In this quiz, we focus on findings from a recent phase three clinical trial that tested different doses of this new oral medication. Test your knowledge of upadacitinib in this quiz.
In this slideshow, we feature results from some noteworthy rheumatoid arthritis studies that were recently published: improved patient-reported outcomes in refractory rheumatoid arthritis with use of a JAK inhibitor, mortality risk with coronary microvascular dysfunction similar in rheumatoid arthritis and diabetes, prescriber preference affects the length of time a patient takes a conventional synthetic DMARD before switching to a biologic DMARD, and more.
